[go: up one dir, main page]

NO20071946L - Stable liquid formulations of plasmid DNA - Google Patents

Stable liquid formulations of plasmid DNA

Info

Publication number
NO20071946L
NO20071946L NO20071946A NO20071946A NO20071946L NO 20071946 L NO20071946 L NO 20071946L NO 20071946 A NO20071946 A NO 20071946A NO 20071946 A NO20071946 A NO 20071946A NO 20071946 L NO20071946 L NO 20071946L
Authority
NO
Norway
Prior art keywords
plasmid dna
plasmid
dna
stable
liquid formulations
Prior art date
Application number
NO20071946A
Other languages
Norwegian (no)
Inventor
Michel Couder
Francis Blanche
Nicolas Maestrali
Thierry Guillemin
David Gaillac
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/011437 external-priority patent/WO2005026331A2/en
Priority claimed from PCT/EP2005/005213 external-priority patent/WO2005100542A1/en
Application filed by Centelion filed Critical Centelion
Publication of NO20071946L publication Critical patent/NO20071946L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Denne oppfinnelse er relatert til plasmid DNA væskeformuleringer som er stabile og forblir udegradert ved +4 ?C til romtemperatur for lange tidsperioder, og er derfor nyttige for lagring av plasmid DNA som er benyttet i forskning, plasmidbasert terapi, slik som DNA vaksine og genterapi. Den foreliggende oppfinnelse er også relatert til en fremgangsmåte for å konservere plasmid DNA i en stabil form over tid ved +4 ?C til romtemperatur. Den foreliggende oppfinnelse er også relatert til stabile plasmid DNA væskesammensetninger for anvendelse i en fremgangsmåte for å behandle menneskekroppen eller dyrekroppen ved plasmidbasert terapi, slik som DNA vaksinasjon eller genterapi.This invention relates to plasmid DNA fluid formulations that are stable and remain degraded at +4 ° C to room temperature for long periods of time, and are therefore useful for storing plasmid DNA used in research, plasmid-based therapy, such as DNA vaccine and gene therapy. The present invention is also related to a method of conserving plasmid DNA in a stable form over time at + 4 ° C to room temperature. The present invention is also related to stable plasmid DNA fluid compositions for use in a method of treating the human or animal body by plasmid-based therapy, such as DNA vaccination or gene therapy.

NO20071946A 2004-09-17 2007-04-17 Stable liquid formulations of plasmid DNA NO20071946L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2004/011437 WO2005026331A2 (en) 2003-09-17 2004-09-17 Method of preparation of pharmaceutically grade plasmid dna
PCT/EP2005/005213 WO2005100542A1 (en) 2004-04-19 2005-04-19 Method for purifying plasmid dna
PCT/EP2005/010881 WO2006029908A1 (en) 2004-09-17 2005-09-19 Stable liquid formulations of plasmid dna

Publications (1)

Publication Number Publication Date
NO20071946L true NO20071946L (en) 2007-05-29

Family

ID=56290732

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071946A NO20071946L (en) 2004-09-17 2007-04-17 Stable liquid formulations of plasmid DNA

Country Status (14)

Country Link
EP (1) EP1791945A1 (en)
JP (1) JP2008512997A (en)
KR (1) KR20070058621A (en)
CN (1) CN101040041A (en)
AU (1) AU2005284244A1 (en)
BR (1) BRPI0515553A (en)
CA (1) CA2579340A1 (en)
EA (1) EA011554B1 (en)
IL (1) IL181753A0 (en)
MX (1) MX2007003214A (en)
NO (1) NO20071946L (en)
NZ (1) NZ553914A (en)
TN (1) TNSN07087A1 (en)
WO (1) WO2006029908A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2542385C2 (en) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Method for preparing pharmaceutical composition for inducing angiogenesis in tissues, pharmaceutical composition prepared by this method, and method of treating individual's tissue and/or organ ischemia
CN104032005B (en) * 2014-06-12 2015-11-25 成都中创清科医学检验所有限公司 A kind of preservatives of PCR order-checking intermediate product and store method
MX2017008730A (en) * 2014-12-29 2017-11-17 Bonac Corp Composition containing nucleic acid molecule stably.
RU2612497C2 (en) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Optimized nucleotide sequence and pharmaceutical compositions based thereon with sustained vegf transgene expression
RU2628087C1 (en) * 2016-09-01 2017-08-14 Игорь Валериевич Корниенко Composition with antimicrobial action for storage of dna or dna-containing preparations (versions) and its application
CN106554956A (en) * 2016-12-07 2017-04-05 安徽智飞龙科马生物制药有限公司 A kind of method that industrialization prepares BCG CpG DNA
WO2019023937A1 (en) * 2017-08-01 2019-02-07 深圳华大智造科技有限公司 Highly efficient endonuclease buffer system
EP3673082A4 (en) * 2017-08-25 2021-05-26 Zoetis Services LLC A nucleic acid probe, a method of immobilizing the nucleic acid to a solid support using uv light, a solid support comprising an immobilized nucleic acid probes, and a test device comprising a solid support
EP3714252B1 (en) 2017-11-22 2023-05-31 Beckman Coulter, Inc. Diluent preparation module und method for supplying such diluent
CN112639119A (en) * 2018-08-30 2021-04-09 葛兰素史密斯克莱知识产权发展有限公司 Method for detecting nucleic acid
CN111718961B (en) * 2019-07-03 2022-02-08 华大青兰生物科技(无锡)有限公司 Method for transforming bacteria by using plasmid
CN115404232A (en) * 2021-05-10 2022-11-29 艾棣维欣(苏州)生物制品有限公司 Method for extracting plasmid DNA from bacteria
KR20230141965A (en) * 2022-03-24 2023-10-10 주식회사 헬릭스미스 Liquid formulation pharmaceutical composition comprising plasmid DNA

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
FR2773818B1 (en) * 1998-01-21 2000-02-18 Pasteur Merieux Serums Vacc BACTERIA LYSIS PROCESS AND DEVICE
AU782193B2 (en) * 1999-12-17 2005-07-07 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef

Also Published As

Publication number Publication date
JP2008512997A (en) 2008-05-01
IL181753A0 (en) 2007-07-04
AU2005284244A1 (en) 2006-03-23
EA011554B1 (en) 2009-04-28
NZ553914A (en) 2009-11-27
EA200700656A1 (en) 2007-10-26
CA2579340A1 (en) 2006-03-23
KR20070058621A (en) 2007-06-08
CN101040041A (en) 2007-09-19
TNSN07087A1 (en) 2008-06-02
BRPI0515553A (en) 2008-07-29
EP1791945A1 (en) 2007-06-06
WO2006029908A1 (en) 2006-03-23
MX2007003214A (en) 2007-10-11

Similar Documents

Publication Publication Date Title
NO20071946L (en) Stable liquid formulations of plasmid DNA
BR0210839A (en) Recombination system, method for removing a chromosomal DNA DNA sequence from a eukaryotic cell or organism, organism, cell culture, organ, tissue, part or material of transgenic propagation, and use of an organism or cell culture , transgenic propagating organ, tissue, part or material
NO20073814L (en) GLP-1 agonists, compositions, methods and applications
SG146691A1 (en) Methods of preparing and using stem cell compositions and kits comprising the same
NO20092227L (en) Salts and crystal forms of 2-methyl-2- [4- (3-methyl-2-oxo-8-conolin-3-yl-2,3-dihydro-imidazo [4,5-C] quinolin-1-yl) phenyl] -propionitrile
BRPI0414867A (en) pyrazolopyridines and their analogues
NO20064953L (en) Human GLP-1 mimetic bodies, compositions, methods and applications
NO20075992L (en) Compounds that modulate C-Kit and C-FMS activity and uses thereof
NO20081482L (en) Delta and epsilon crystal forms for imatinib mesylate
BR112015005674A2 (en) hppd variants and methods of use
ATE447574T1 (en) 3-AMINO-4-PHENYLBUTANIC ACID DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
NO20073059L (en) 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS
NO20082684L (en) F, G, H, I and K crystal forms of imatinib mesylate
ATE538651T1 (en) SPIROPIPERIDINE INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NO20072005L (en) New heterocyclic amides
NO20061033L (en) Compositions and Methods for Delivery of Biologically Active Agents
MX2007004841A (en) Triazoles useful as inhibitors of protein kinases.
NO20061138L (en) Fermentation cell walls for the treatment or prevention of hyperglycemia or to stabilize glycemia
DK1758860T3 (en) Saturated and unsaturated 3-pyridylbenzocycloalkylmethylamines for the treatment of pain, depression and anxiety
EA200700613A1 (en) METABOLICALLY ACTIVE MICROORGANISMS AND METHODS OF THEIR RECEIVING
MX2021001347A (en) Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof.
NO20070640L (en) Improved aprotinin additives
NO20082098L (en) AICA riboside formulations
ZA200701798B (en) Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalioproteinases inhibitors
ATE527377T1 (en) CREATION OF GENE EXPRESSION PROFILES FROM FFPE SAMPLES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application